Monoclonal antibodies targeting CD19 on B cells to mediate immune killing of malignant B cells.
Monoclonal IgG antibodies that bind CD19 on B cells and induce immune-mediated killing of malignant CD19+ cells via Fc-dependent mechanisms (ADCC, ADCP) and complement-dependent cytotoxicity, leading to B-cell depletion and potential direct apoptotic signaling.
YES
DIRECT
Antibody binding to CD19 opsonizes B cells and triggers Fc-dependent effector functions (ADCC by NK cells, ADCP by macrophages) and complement-dependent cytotoxicity; may also induce apoptotic signaling upon receptor crosslinking.
Antibody-drug conjugates targeting CD19 that internalize into B cells and release a cytotoxic payload to kill malignant cells.
An anti‑CD19 monoclonal antibody binds CD19 on B cells, is internalized, and releases an intracellular cytotoxic payload via linker cleavage, disrupting DNA/mitosis and inducing apoptosis of malignant CD19+ cells (with potential ancillary Fc‑mediated effector activity).
YES
DIRECT
The anti‑CD19 ADC binds CD19, is internalized, and releases a cytotoxic payload after linker cleavage, disrupting DNA/mitosis and inducing apoptosis of CD19+ cells (with possible ancillary Fc‑mediated ADCC/CDC).
Antibody-drug conjugates targeting CD79b (a B-cell receptor component) that internalize and release cytotoxins to kill B-cell lymphomas.
Monoclonal antibody binds CD79b on B-cell receptor, is internalized, and releases its linked cytotoxic payload intracellularly to kill malignant B cells (e.g., via microtubule/DNA damage and apoptosis), with potential Fc-mediated effector contributions.
YES
DIRECT
ADC binds CD79b on B cells, is internalized, and releases a cytotoxic payload that disrupts microtubules/DNA and triggers apoptosis; Fc effector functions (ADCC/CDC) may contribute.
Antibody-drug conjugates targeting CD79b (a B-cell receptor component) that internalize and release cytotoxins to kill B-cell lymphomas.
Monoclonal antibody binds CD79b on B-cell receptor, is internalized, and releases its linked cytotoxic payload intracellularly to kill malignant B cells (e.g., via microtubule/DNA damage and apoptosis), with potential Fc-mediated effector contributions.
NO
INDIRECT
The ADC targets CD79b on B cells, is internalized, and releases a payload that binds β-tubulin (vinca site) to disrupt microtubules and induce apoptosis; β-tubulin expression is not the basis of target cell selection.
Bispecific antibodies that bind CD20 on B cells and CD3 on T cells to redirect T-cell cytotoxicity against CD20-positive malignant B cells.
Bispecific antibodies that bind CD20 on B cells and CD3 on T cells, bringing T cells into close proximity with CD20+ malignant B cells to form an immunologic synapse and activate T-cell cytotoxicity (perforin/granzyme), leading to MHC-independent killing of target B cells.
YES
DIRECT
CD20×CD3 bispecific antibodies bridge CD20 on B cells to CD3 on T cells, forming an immunologic synapse that activates T-cell cytotoxicity to kill CD20+ cells via perforin/granzyme (MHC-independent).